R1-ICR-5 是一种高选择性的 RIPK1 PROTAC 降解剂,通过 VHL 介导促使 RIPK1 降解,进而失调 TNFR1 和 TLR3/4 信号枢纽,增强 NF-κB、MAPK 和 IFN 信号输出,同时促进 RIPK3 激活和坏死性凋亡 (necroptosis),可用于三阴性乳腺癌和皮肤炎症的研究(粉色:RIPK1 配体 (MS-C38546);蓝色:VHL 配体 (MS-L68940);黑色:连接子 (MS-N63798))。
产品编号: MS-Z11043 纯度: 98.73% CAS No.: 3070346-91-4 分子式: C54H70N8O7S2 分子量: 1007.31
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

R1-ICR-5 是一种高选择性的 RIPK1 PROTAC 降解剂,通过 VHL 介导促使 RIPK1 降解,进而失调 TNFR1 和 TLR3/4 信号枢纽,增强 NF-κB、MAPK 和 IFN 信号输出,同时促进 RIPK3 激活和坏死性凋亡 (necroptosis),可用于三阴性乳腺癌和皮肤炎症的研究(粉色:RIPK1 配体 (MS-C38546);蓝色:VHL 配体 (MS-L68940);黑色:连接子 (MS-N63798))。

生物实验数据

生物活性 R1-ICR-5 is a highly selective RIPK1 PROTAC degrader that promotes VHL-mediated degradation of RIPK1, thereby dysregulating the TNFR1 and TLR3/4 signaling hubs, enhancing NF-κB, MAPK, and IFN signaling outputs, and promoting RIPK3 activation and necroptosis, and it can be used for research on triple-negative breast cancer and skin inflammation (pink: RIPK1 ligand (MS-C38546); blue: VHL ligand (MS-L68940); black: linker (MS-N63798)).
体外研究
(In Vitro)

R1-ICR-5 (1 μM; 2-24 h) 可在小鼠骨髓来源巨噬细胞 (BMDMs) 中诱导呈时间依赖性、VHL 及蛋白酶体依赖性的 RIPK1 降解,且对相关激酶无脱靶效应。
R1-ICR-5 (20 h) 强效降解人源 HT1080、HT29 细胞及小鼠源 EMT6、L929 细胞中的内源性 RIPK1 蛋白。
R1-ICR-5 (1 μM; 24 h) 会导致小鼠 Mlkl-/- BMDMs 中 RIPK1 的再合成速率降低,在初始用 1 μM R1-ICR-5 处理后洗脱,其蛋白水平需超过 72 h 才能恢复至处理前水平。
R1-ICR-5 (1 μM; 4 h) 可增强 TNF 诱导的小鼠 BMDMs 中 NF-κB 靶基因 Tnf、A20 和 Sod2 的表达。
R1-ICR-5 (1 μM; 4 h) 可增强小鼠 BMDMs 中由 TLR3 介导的 NF-κB 和 IFN 靶基因的表达。
R1-ICR-5 (1 μM; 18 h) 可使人类 HT1080 细胞对 TNF 诱导的坏死性凋亡增敏。
R1-ICR-5 (1 μM; 5 h) 可使小鼠 BMDMs 对 TNF 诱导的坏死性凋亡增敏。
R1-ICR-5 (1 μM; 24 h) 可诱导小鼠 BMDMs 发生自分泌 TNF 介导的坏死性凋亡,该过程依赖于 TNFR1 信号通路及 MK2 介导的 TNF 生物合成。
R1-ICR-5 (1 μM; 24 h) 可增强小鼠 EO771 三阴性乳腺癌 (TNBC) 细胞对辐射诱导坏死性凋亡的敏感性。

Western Blot Analysis

Cell Line: mouse bone marrow-derived macrophages (BMDMs)
Concentration: 1 μM (R1-ICR-5); 1 μM VH298 (VHL inhibitor, pre-incubation); 100 nM bortezomib (proteasome inhibitor, pre-incubation)
Incubation Time: 2 h, 4 h, 6 h, 12 h, 24 h (R1-ICR-5 treatment); 1 h (VH298/bortezomib pre-incubation, followed by R1-ICR-5 treatment)
Result: Caused RIPK1 degradation as early as 2 h, nearly complete by 6 h, and sustained through 24 h.
Blocked RIPK1 degradation when cells were pre-treated with VH298 or bortezomib.
Did not cause significant changes in protein levels of related kinases RIPK2, RIPK3, BRAF, or TrkA.

Western Blot Analysis

Cell Line: mouse Mlkl-/- bone marrow-derived macrophages (BMDMs)
Concentration: 1 μM
Incubation Time: 24 h (initial treatment); 24 h, 48 h, 72 h (post-washout harvesting)
Result: Kept RIPK1 protein levels suppressed at 24 h post-washout, with levels beginning to recover by 48 h but not returning to pre-treatment levels even at 72 h post-washout.

Real Time qPCR

Cell Line: mouse bone marrow-derived macrophages (BMDMs)
Concentration: 1 μM (R1-ICR-5 pre-incubation)
Incubation Time: 4 h (R1-ICR-5 pre-incubation); 2 h, 4 h, 6 h (subsequent TNF treatment)
Result: Accentuated TNF-induced upregulation of NF-κB target genes Tnf, A20, and Sod2, with significant increases in fold induction compared to DMSO controls (p<0.0001 for Tnf at 4 h, 6 h; p<0.001 for A20 at 6 h; p<0.0001 for Sod2 at 4 h, 6 h).

Real Time qPCR

Cell Line: mouse bone marrow-derived macrophages (BMDMs)
Concentration: 1 μM (R1-ICR-5 pre-incubation)
Incubation Time: 4 h (R1-ICR-5 pre-incubation); unspecified (subsequent Poly(I:C) stimulation)
Result: Significantly enhanced Poly(I:C)-induced expression of NF-κB target genes Tnf, Il6, Ccl2 and IFN target genes Cxcl10, Cxcl9, Ifnb, with fold inductions significantly higher than DMSO controls (p<0.0001 for all genes).
体内研究
(In Vivo)

R1-ICR-5 (40 µg/次; 瘤内注射; 共 3 剂) 联合 8 Gy 放疗可增强抗肿瘤免疫,将中位生存期延长至 35 天,诱导持久的肿瘤消退,并在小鼠原位三阴性乳腺癌模型中产生具有保护性的抗肿瘤免疫记忆。
R1-ICR-5 (40 µg/次; 瘤内注射; 共 3 剂) 联合 4 Gy 放射治疗与抗 CTLA-4 免疫检查点阻断,可在小鼠原位三阴性乳腺癌模型中诱导近乎完全的肿瘤消退,并显著延长生存期。
R1-ICR-5 (40 µg/次; 瘤内注射; 共 4 剂) 与抗 PD-1 免疫检查点阻断疗法联合使用时,可在小鼠原位三阴性乳腺癌模型中延缓肿瘤生长,将应答率提升至 60%,并将中位生存期延长至 36.5 天。
R1-ICR-5 (10 mM; 皮下注射; 单次给药) 可阻断小鼠中由 SMAC 模拟物+泛半胱天冬酶抑制剂联合处理诱导的 RIPK1 依赖性皮肤炎症与组织损伤。
R1-ICR-5 (10 mM; 皮下注射; 单次给药) 可完全抑制小鼠中由 TBK1 抑制和 TNF 介导的皮肤炎症与组织损伤。

Animal Model: C57BL/6J (female, 5-6 weeks old, orthotopic EO771 mammary fat pad tumor model)
Dosage: 40 µg per injection
Administration: intra-tumoral; 3 doses on days 1, 4, 7 post-radiotherapy
Result: Extended median survival to 35 days, compared to 24 days with radiotherapy alone.
Achieved complete tumor regression in 3 out of 10 treated mice, with 2 remaining tumor-free long-term.
Showed complete or partial responses in 50% of treated mice, versus minimal responses with radiotherapy alone.
Increased TNF+IFNγ+ immune cells (CD45+) infiltrating tumors, with elevated counts of TNF+IFNγ+ CD8+ T cells, CD4+ conventional T cells, γδ T cells, NK cells, and NK-T cells per gram of tumor tissue.
Rendered cured mice fully resistant to tumor re-challenge, with 0 out of 2 mice developing new tumors, compared to 7 out of 7 naïve mice.\nStrongly inhibited tumor growth, with 9 out of 10 mice responding to therapy and 8 achieving complete, long-term tumor regression.
Significantly extended survival, with a median survival that was not reached, compared to a median survival of 70.5 days with radiotherapy + anti-CTLA-4 alone.
Animal Model: C57BL/6J (female, 5-6 weeks old, orthotopic EO771 mammary fat pad tumor model)
Dosage: 40 µg per injection
Administration: intra-tumoral; 4 doses on days 2, 4, 6, and 8
Result: Slowed tumor growth kinetics (measured by area under the tumor growth curve) and extended median survival to 36.5 days, compared to 28.5 days with anti-PD-1 alone.
Showed complete or partial responses in 60% of treated mice, with 3 out of 10 mice achieving complete, long-term tumor regression.
Animal Model: C57BL/6 (RIPK1-dependent skin inflammation model)
Dosage: 10 mM
Administration: subcutaneous; single co-injection
Result: Reduced histopathological lesion severity, with a mean Histological Multivariant Lesion Score (HLS) of 55 (range 30-70), compared to a mean HLS of 214 (range 175-257) in mice treated with ASTX660 + emricasan alone.
Prevented deep epidermal ulceration, dermal fibrosis, and cellular necrosis induced by ASTX660 + emricasan.
Animal Model: C57BL/6 (TBK1 inhibition-induced skin inflammation model)
Dosage: 10 mM
Administration: subcutaneous; single co-injection
Result: Completely protected mice from deep skin ulceration and tissue injury induced by TBK1 inhibition + TNF treatment.
性状 固体
颜色 Off-white to light yellow

化学信息

分子量 1007.31
分子式 C54H70N8O7S2
CAS No. 3070346-91-4

储存&溶解度

储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (99.27 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM0.9927 mL4.9637 mL9.9274 mL24.8186 mL
5 mM0.1985 mL0.9927 mL1.9855 mL4.9637 mL
10 mM0.0993 mL0.4964 mL0.9927 mL2.4819 mL
15 mM0.0662 mL0.3309 mL0.6618 mL1.6546 mL
20 mM0.0496 mL0.2482 mL0.4964 mL1.2409 mL
25 mM0.0397 mL0.1985 mL0.3971 mL0.9927 mL
30 mM0.0331 mL0.1655 mL0.3309 mL0.8273 mL
40 mM0.0248 mL0.1241 mL0.2482 mL0.6205 mL
50 mM0.0199 mL0.0993 mL0.1985 mL0.4964 mL
60 mM0.0165 mL0.0827 mL0.1655 mL0.4136 mL
80 mM0.0124 mL0.0620 mL0.1241 mL0.3102 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础